MATF is one of the only high throughput production facilities in the world offering custom-made, high quality, high-affinity monoclonal antibodies.
18 Aug 2016
Monash Partners Accredited ICH Research Good Clinical Practice (GCP) Training Program
From August 2016, Monash University will offer TransCelerate accredited ICH Good Clinical Practice Training in clinical research, expected and recognised by pharmaceutical companies in commercially-sponsored clinical trials. ICH GCP is also increasingly a requirement of human research and ethics committees
29 Sep 2016
How can we predict whether Angelina Jolie would have developed breast cancer? Recent findings from the Consortium of Investigators of Modifiers of BRCA1/2
MPCCC and BDI present this Biomedicine Discovery Seminar featuring guest speaker Professor Georgia Chenevix-Trench, Head of the Cancer Genetics Laboratory and the Department of Genetics and Computational Biology at the QIMR Berghofer in Brisbane
08 Sep 2016
microRNA-7: A tumour suppressor with therapeutic potential
BDI and MPCCC present this Biomedicine Discovery Seminar featuring guest presenter Professor Peter Leedman, Director, Harry Perkins Institute of Medical Research and University of Western Australia
02 Dec 2016
The Monash University Centre for Human Bioethics is pleased to announce the 32nd running of its annual Intesive Bioethics Course on 2–5 December 2016.
Monash part of world-first clinical trial for lymphoma patients
A novel therapy for aggressive lymphoma is being tested in a world-first clinical trial at the Monash Health Translation Precinct (MHTP).
New class of anti-cancer agents may be promising treatment for multiple myeloma
Australian researchers have discovered that a new class of anti-cancer agents may be effective in treating multiple myeloma, an incurable bone marrow cancer.
First patient overnight stay at MHTP Clinical Trials Centre
Mr Rudy Van Ekeren is the second aggressive B-cell lymphoma patient in Australia—and only the third in the world—to receive a novel epigenetic therapy as part of an anti-lymphoma clinical trial. The study is being led by Monash University researcher and Monash Health haematologist Dr Gareth Gregory.
Double blow for lung cancer and emphysema offers hope to patients
Lung cancer and emphysema could be diagnosed earlier and targeted with an existing drug, vastly improving patient outcomes, researchers at Hudson Institute of Medical Research have discovered.